

## **THE BASICS OF FLUID BIOMARKERS IN ALZHEIMER'S DISEASE**

Friday, July 14, 2023 | 8 a.m. – 5 p.m.  
Hilton (Diamond Room) — Amsterdam, Netherlands  
All times are in Central European Time  
In-person attendance only

### **Overview**

The Basic of Fluid Biomarkers in Alzheimer's Disease was organized by leading scientists in this field and by the Alzheimer's Association Global Biomarkers Standardization Consortia (GBSC) and the ISTAART Biofluid Based Biomarkers PIA. The fluid biomarkers field for Alzheimer's disease (AD), and other dementias is rapidly expanding. This workshop aims to provide participants with an in-depth understanding of the fundamental principles, inherent limitations, and clinical and research applications of the most common AD biomarkers present in cerebrospinal fluid (CSF) and blood.

This workshop will include fundamental laboratory-focused sessions that capture the basics of neurochemistry, sample pre-analytics, assay methods and development, quality control, and regulatory considerations. It will also incorporate clinical practice-focused sessions that cover considerations for AD fluid biomarker implementation, the context of use, disclosure, and the gaps and opportunities in this field. These sessions will cover both standard AD biomarkers and emerging biomarkers and novel platforms in development. Lectures will be followed by interactive Q&A sessions and discussions to ensure that participants understand the current and future state of fluid biomarkers.

### **Organizing Committee**

- Alicia Algeciras-Schimmich, Mayo Clinic, United States
- Ulf Andreasson, University of Gothenburg, Sweden
- Kaj Blennow, The Sahlgrenska Academy at University of Gothenburg, Sweden
- Michelle Mielke, Wake Forest University School of Medicine, United States
- Markus Otto, Martin Luther University Halle-Wittenberg, Germany
- Jonathan Schott, University College London, United Kingdom
- Charlotte Teunissen, VU University Medical Center, Netherlands
- Henrik Zetterberg, The Sahlgrenska Academy at University of Gothenburg, Sweden

### **Target Audience**

This workshop can serve as a beginner or refresher course targeted for research investigators, clinicians, residents, fellows, and graduate and postgraduate students.

## Learning Objectives

- Provide an in-depth understanding of the fundamental principles, inherent limitations, and clinical and research applications of the most common biomarkers used in AD and found in CSF and blood.
- Provide an overview of the fundamentals of CSF physiology, basics of neurochemistry, technical issues of sample collection, storage, analysis methods, quality control, and regulatory issues.
- Cover the latest in cutting-edge biomarker technology, including blood-based biomarkers, with the current understanding of how biomarkers track the progression in AD and their use in other dementias.

## Registration

Educational workshops are offered for in-person attendance only. Workshops require a separate registration fee in addition to AAIC full conference registration, or they may be purchased as stand-alone events.

Before attending, attendees are encouraged to watch the Basics of Fluid Biomarkers webinars to cover preliminary information.

## Agenda

Time	Session Details	Speakers
7-8 a.m.	<b>Breakfast</b>	
<b>Session 1: Laboratory — Basics</b>		
8:15-8:20 a.m.	<b>Opening Remarks</b>	
8:20-8:45 a.m.	<b>Overview of Core CSF Alzheimer's Disease Biomarkers</b>	Kaj Blennow
8:45-9:10 a.m.	<b>Overview of Core Blood Based Alzheimer's Disease Biomarkers</b>	Henrik Zetterberg
9:10-9:35 a.m.	<b>Emerging Fluid Biomarkers for Alzheimer's Disease</b>	Thomas Karikari
9:35-10 a.m.	<b>Non-AD Biomarkers (FTD, LBD, DS/AD, TBI, VCID)</b>	Marta Del Campo
10-10:20 a.m.	<b>Discussion and Poll Questions</b>	

10:30-10:50 a.m.	<b>Break</b>	
<b>Session 2: Laboratory — Analytics (Refresher)</b>		
10:50-11:10 a.m.	<b>5 Things to Know: CSF and Blood Biomarkers and Analytics</b>	Inge Verberk
11:10-11:25 a.m.	<b>Regulatory Considerations for Implementation of Biomarkers</b>	Alicia Algeciras-Schimmich
11:25-11:45 a.m.	<b>WHO Initiative: Requirements for Global Use of Biomarkers</b>	Pedro Rosa-Neto
11:45 a.m. – 12:05 p.m.	<b>Discussion</b>	
12:05-1:05 p.m.	<b>Lunch</b>	
<b>Session 3: Clinical — Risk, Clinical Trial Enrichment and Confounders</b>		
1:05-1:30 p.m.	<b>Use of Fluid – Omics for Risk and Dementia Diagnosis</b>	Yanaika Hok-A-Hin
1:30-1:55 p.m.	<b>Effects of Sociodemographics, Medical Comorbidities, Drugs on Biomarkers</b>	Michelle Mielke
1:55-2:20 p.m.	<b>Using Biofluid Markers for Clinical Trial Enrichment and Pharmacodynamics</b>	Jeff Dage
2:20-2:40 p.m.	<b>Discussion and Poll Question</b>	
2:40-3 p.m.	<b>Break</b>	
<b>Session 4: Clinical — Case Based Approaches</b>		
3-3:30 p.m.	<b>Appropriate Use Recommendations and Context of Use for CSF Biomarkers for Alzheimer's Disease and Other Dementia (Case-Based Approach)</b>	Jonathan Schott
3:30-4 p.m.	<b>Appropriate Use Recommendations and Context of Use for Blood Biomarkers for Alzheimer's Disease (Case-Based Approach)</b>	Sebastian Palmqvist
4-4:20 p.m.	<b>Discussion and Poll Question</b>	
4:20-4:25 PM	<b>Closing Remarks</b>	